Efferon

Efferon is a German medical-technology brand and biotech company based in Tuttlingen, Germany, that develops and manufactures multimodal hemoadsorption devices for extracorporeal blood purification. Its products are single-use, CE-marked devices used in acute critical-care settings to remove bacterial endotoxin and excessive cytokines directly from the bloodstream, addressing key molecular drivers of sepsis, septic shock, cytokine release syndrome (CRS) and endotoxemia. The company positions itself around the scale of the sepsis problem, citing roughly 166 million cases a year worldwide, about 42% hospital mortality in adults with septic shock, and the fact that half of the world's annual sepsis burden falls on children. Efferon's core technology is a polymeric adsorbent — a macroporous hypercrosslinked styrene-divinylbenzene copolymer with an immobilized LPS-selective ligand — contained in a polycarbonate column. The flagship adult device, Efferon LPS, selectively adsorbs lipopolysaccharides while non-selectively adsorbing cytokines, myoglobin, cellular debris and other toxic substances. It can be run as isolated hemoadsorption or combined with renal replacement therapy (RRT), ECMO and cardiopulmonary bypass (CPB). A second product, Efferon NEO, is described as the first CE-marked single-use multimodal extracorporeal blood purification device purpose-built for pediatric sepsis and septic shock, and it received CE MDR marking. According to the company, more than 30,000 treatments have been administered, including roughly 1,000 pediatric and 50 neonatal patients, and the devices are approved and in clinical use in 45 countries. Efferon reports up to 40% lower per-patient resource use in the ICU. Beyond critical care, the company is developing applications in post-acute inflammatory syndromes, oncology and immunotherapy-related inflammation, and immune-mediated systemic diseases. The company was founded by Dima Romashin, who serves as Founder and CEO and leads corporate strategy, capital formation and global expansion. Co-founder and Chief Technology Officer Ivan Bessonov originated the core technology and leads R&D, technology development and scientific collaborations. Alexandru Bojan heads international sales. Efferon presents itself as a biotech company equipping physicians with innovative extracorporeal therapies that restore immune balance and improve patient outcomes, and it frames its mission around making effective sepsis therapy available at scale.

Efferon is a German biotech and medical-device company based in Tuttlingen, Germany, that develops multimodal hemoadsorption devices for extracorporeal blood purification. The company was founded by Dima Romashin, a serial entrepreneur who previously served as an executive in a large manufacturing enterprise with over $100 million in annual revenue and who leads Efferon's corporate strategy, capital formation and global expansion. Co-founder and Chief Technology Officer Ivan Bessonov originated the company's core technology; he brought more than 20 years of expertise in functional polymeric materials and composites and more than 10 years in the medical device industry, with prior experience spanning academia — including scaffold development for tissue engineering at Moscow State University — and industry, including glass-fiber composites at Bautex. The company's technology centers on a polymeric adsorbent: a macroporous hypercrosslinked styrene-divinylbenzene copolymer with an immobilized LPS-selective ligand, supplied suspended in saline within a polycarbonate column. This design allows the device to selectively adsorb lipopolysaccharides while non-selectively adsorbing cytokines, myoglobin, cellular debris and endogenous and exogenous toxic substances. The flagship adult product, Efferon LPS, is a CE-marked, single-use multimodal extracorporeal blood purification device intended for acute settings to treat sepsis, septic shock, cytokine storm and endotoxemia. It can be used as isolated hemoadsorption or in combination with renal replacement therapy (RRT), ECMO and cardiopulmonary bypass (CPB). In the multicenter randomized LASSO trial, treatment with Efferon LPS was associated with faster resolution of septic shock and improved hemodynamic stability, including a rapid increase in mean arterial pressure and reduced vasopressor requirements, as well as shorter shock duration. Efferon later introduced Efferon NEO, described as the first CE-marked single-use multimodal extracorporeal blood purification device ever purpose-built to treat pediatric sepsis and septic shock. The company announced that Efferon NEO received CE MDR marking. According to Efferon, more than 30,000 treatments have been administered with its devices, including approximately 1,000 pediatric and 50 neonatal patients, and the products are approved and in clinical use in 45 countries worldwide. The company reports up to 40% lower per-patient resource use in the ICU. Efferon frames its work around the global burden of sepsis, citing roughly 166 million cases a year worldwide, about 42% hospital mortality in adults with septic shock, a 59% mortality rate reported after six months, and the fact that 50% of the world's annual sepsis burden falls on children. While its devices are approved and in clinical use for critical care, the company is developing additional applications in post-acute inflammatory syndromes, oncology and immunotherapy-related inflammation, and immune-mediated systemic diseases. Efferon describes itself as a biotech company manufacturing multimodal hemoadsorption devices that remove endotoxins and inflammatory mediators from the bloodstream, with the goal of equipping physicians with innovative extracorporeal therapies that restore immune balance and improve patient outcomes.

• Efferon founded by Dima Romashin

• Efferon LPS CE-marked and in clinical use for sepsis, septic shock, cytokine storm and endotoxemia

• Efferon NEO receives CE MDR mark as first pediatric-purpose-built multimodal hemoadsorption device

• 30,000+ treatments administered across 45 countries

Clinically validated multimodal hemoadsorption technology for sepsis, septic shock and cytokine storm; first and only pediatric-approved multimodal therapy for these indications.

• Efferon LPS

  CE-marked, single-use multimodal extracorporeal blood purification device for adults, used in acute settings to treat sepsis, septic shock, cytokine storm and endotoxemia. Contains a macroporous hypercrosslinked styrene-divinylbenzene copolymer with immobilized LPS-selective ligand; 210 ml total internal volume, 190 ml adsorbent volume, 350 g weight.

• Efferon NEO

  The first CE-marked single-use multimodal extracorporeal blood purification device purpose-built to treat pediatric sepsis and septic shock.

1. 1Efferon official websiteefferon.com
2. 2About Efferonefferon.com
3. 3Indications & Productsefferon.com
4. 4Efferon LPSefferon.com
5. 5Efferon on Wikidatawikidata.org